FDA Expands OTC CGM Access to Children - Summary - MDSpire

FDA Expands OTC CGM Access to Children

  • By

  • Kathryn Wighton

  • June 15, 2026

  • 2 min

Share

Objective:

To provide access to the Dexcom Stelo Glucose Biosensor System for children aged 2 years and older who do not use insulin.

Approach:
    Key Findings:
    • The device is designed for children aged 2 years and older.
    • Each sensor lasts up to 15 days, with potential shorter wear time in pediatric patients.
    • Mild adverse events reported include local infection, skin irritation, and discomfort.
    Interpretation:

    The device is not suitable for patients with problematic hypoglycemia or those receiving dialysis.

    Limitations:
    • Does not provide alerts for low glucose levels.
    • Patients with a history of disordered eating should consult a healthcare provider before use.
    Conclusion:

    The clearance aligns with the FDA's initiative to support home healthcare devices.

    Sources:

Original Source(s)

Related Content